

# Accepted Manuscript

Successful Use of Bortezomib Lenalidomide Combination as Treatment for a Patient with Plasmablastic Lymphoma

William D. Marrero, MD, Alexis Cruz-Chacón, MD, Christian Castillo, MD, Fernando Cabanillas, MD

PII: S2152-2650(18)30218-0

DOI: [10.1016/j.clml.2018.04.011](https://doi.org/10.1016/j.clml.2018.04.011)

Reference: CLML 1104

To appear in: *Clinical Lymphoma, Myeloma and Leukemia*


Received Date: 27 February 2018

Revised Date: 5 April 2018

Accepted Date: 27 April 2018

Please cite this article as: Marrero WD, Cruz-Chacón A, Castillo C, Cabanillas F, Successful Use of Bortezomib Lenalidomide Combination as Treatment for a Patient with Plasmablastic Lymphoma, *Clinical Lymphoma, Myeloma and Leukemia* (2018), doi: 10.1016/j.clml.2018.04.011.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



## Successful Use of Bortezomib Lenalidomide Combination as Treatment for a Patient with Plasmablastic Lymphoma

Authors: William D. Marrero, MD<sup>1</sup>; Alexis Cruz-Chacón, MD<sup>1</sup>; Christian Castillo, MD<sup>1</sup>  
Fernando Cabanillas, MD<sup>1</sup>

<sup>1</sup>Auxilio Mutuo Hospital Cancer Center

### Clinical Practice Points

- Most of the Plasmablastic lymphoma cases are present in HIV patients.
- We present a case of Plasmablastic lymphoma with parotid gland involvement in an HIV negative patient, with complete response to Bortezomib and Lenalidomide.
- Bortezomib and Lenalidomide are drugs with excellent results in multiple myeloma.
- Currently there is no standard of care for Plasmablastic lymphoma and the majority of cases have a poor outcome.

### Abstract

Plasmablastic lymphoma (PBL) is an unusual disorder which shares some features with myeloma. The vast majority of cases have been reported in human immunodeficiency virus (HIV) positive patients. It usually presents in the oral cavity and is considered as an aggressive lymphoma with a very poor prognosis for which there is no standard of care. Despite treatment most of the patients have a suboptimal outcome. Here we present a case of PBL presenting in the parotid gland of an HIV negative patient who upon relapse responded well to a regimen that included bortezomib and lenalidomide, drugs with excellent activity in myeloma.

### Introduction

PBL is a rare type of Non-Hodgkin lymphoma (NHL) with a predilection for the oral cavity. It is more commonly found in elderly patients infected with HIV and Epstein-Barr-Virus (EBV). Since its description in 1997 [1], the vast majority of cases have been described in HIV positive patients [2]. Some instances have been described in HIV negative patients involving other organs; one-third of these occurred in patients treated

Download English Version:

<https://daneshyari.com/en/article/8615348>

Download Persian Version:

<https://daneshyari.com/article/8615348>

[Daneshyari.com](https://daneshyari.com)